## Tyrosylleucine TFA

Cat. No.:	HY-122794A	
CAS No.:	66852-01-5	O O OH
Molecular Formula:	$C_{17}H_{23}F_{3}N_{2}O_{6}$	
Molecular Weight:	408.37	HO NH <sub>2</sub> H
Target:	Others	Ö
Pathway:	Others	Е ОН
Storage:	Sealed storage, away from moisture	F F
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.4488 mL	12.2438 mL	24.4876 mL		
		5 mM	0.4898 mL	2.4488 mL	4.8975 mL		
		10 mM	0.2449 mL	1.2244 mL	2.4488 mL		
	Please refer to the so	lubility information to select the app	propriate solvent.				
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution					
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution					
		<ol> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (6.12 mM); Clear solution</li> </ol>					

BIOLOGICAL ACTIVITY				
Description	Tyrosylleucine (Tyr-Leu, YL) TFA, an orally active dipeptide, exhibits a potent antidepressant-like activity <sup>[1]</sup> .			
In Vitro	Tyrosylleucine (Tyr-Leu, YL) increases the amount of cells expressing c-Fos, a marker for neuronal activity, in the dentate gyrus of the hippocampus <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Tyrosylleucine (Tyr-Leu, YL) dose-dependently exhibits potent anxiolytic-like activity (0.1-1 mg/kg, i.p.) <sup>[2]</sup> .			



\_\_\_\_\_

Product Data Sheet

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Takafumi Mizushige, et al. Dipeptide tyrosyl-leucine exhibits antidepressant-like activity in mice. Sci Rep. 2020 Feb 10;10(1):2257.

[2]. Norimasa Kanegawa, et al. Dipeptide Tyr-Leu (YL) exhibits anxiolytic-like activity after oral administration via activating serotonin 5-HT1A, dopamine D1 and GABAA receptors in mice. FEBS Lett. 2010 Feb 5;584(3):599-604.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA